An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, significantly improving survival outcomes and redefining curative treatment strategies.
An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with high-risk T2N0 disease.
An expert discusses how KEYNOTE-905 establishes a new evidence-based systemic therapy option that transforms the management and prognosis of patients with muscle-invasive bladder cancer.
An expert discusses strategies for optimizing perioperative immunotherapy use, managing toxicity, and ensuring adherence as KEYNOTE-905 transitions from trial evidence to clinical practice.
An expert discusses how KEYNOTE-905 sets the stage for the next generation of bladder cancer research and multidisciplinary care, shaping the evolving future of MIBC treatment.
